Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chapter 15: HPV vaccine use in the developing world.

Mark A Kane1, Jacqueline Sherris, Pierre Coursaget

  • 1World Health Organization, Seattle, WA, USA. Mark.a.kane@gmail.com

Vaccine
|September 5, 2006
PubMed
Summary

Access to the human papillomavirus (HPV) vaccine and cervical cancer screening is limited in developing nations. Global collaboration is essential to accelerate vaccine availability and affordability for maximum impact.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preschool or Infant Human Papillomavirus Immunization?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Immunogenicity and safety of measles-mumps-rubella vaccine delivered by the aerosol, intradermal and intramuscular routes in previously vaccinated young adults: a randomized controlled trial protocol.

PloS one·2025
Same author

Prevalence of IgG antibodies against Malawi polyomavirus in patients with autoimmune diseases and lymphoproliferative disorders subjected to bone marrow transplantation.

Frontiers in immunology·2024
Same author

Prophylactic cancer vaccines: development and challenges for HBV and HPV vaccines in Latin America.

Salud publica de Mexico·2023
Same author

Population-Level Risk Factors Related to Measles Case Fatality: A Conceptual Framework Based on Expert Consultation and Literature Review.

Vaccines·2023
Same author

Implementing WHO guidance on conducting and analysing vaccination coverage cluster surveys: Two examples from Nigeria.

PloS one·2021

Area of Science:

  • Public Health
  • Vaccinology
  • Oncology

Background:

  • Cervical cancer, primarily caused by human papillomavirus (HPV), disproportionately affects developing countries.
  • Limited access to HPV vaccines and secondary prevention methods like screening exacerbates this disparity.
  • Industrialized nations are expected to adopt HPV vaccines first, with eventual introduction in developing countries.

Purpose of the Study:

  • To highlight the challenges and opportunities for introducing the HPV vaccine in developing countries.
  • To emphasize the need for comprehensive cervical cancer control strategies.
  • To advocate for collaboration among diverse health sectors to facilitate vaccine accessibility.

Main Methods:

  • The abstract discusses the current landscape of HPV vaccine access and cervical cancer prevention.

Related Experiment Videos

  • It analyzes the projected timeline for vaccine introduction in different global settings.
  • It calls for interdisciplinary collaboration and data analysis to inform policy decisions.

    • Main Results:

    • HPV-related mortality is concentrated in developing regions with restricted access to vaccines and screening.
    • The introduction of HPV vaccines requires a coordinated approach within broader cancer control frameworks.
    • International and national consensus-building is crucial for timely vaccine implementation.

    Conclusions:

    • Accelerating the availability and affordability of HPV vaccines in the developing world is a critical public health challenge.
    • Coordinated efforts between sexual and reproductive health, immunization, and cancer control communities are necessary.
    • The goal is to significantly shorten the timeframe for HPV vaccine deployment compared to historical vaccine introductions.